Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Derivative of endostatin resistant to tumor proteins

A technology of endostatin and its derivatives, which can be applied in the fields of antineoplastic drugs, peptide/protein components, animal/human proteins, etc., and can solve problems such as instability, short half-life of endostatin, and affecting the effect of endostatin on antitumor therapy , to achieve the effect of high anti-tumor biological activity and long half-life

Active Publication Date: 2019-10-11
孙嘉琳 +1
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, in monkey experiments and human clinical trials, it was found that the half-life of endostatin was very short, showing exponential degradation, and the content of endostatin in the body decreased by a hundred times or even close to zero after 10 hours (Acta Pharmacol Sin, 26, 124-128, 2005 ; J Clin Oncol,20,3792-3803,2002), it is shown that it is very unstable in animals, which will greatly affect the antitumor therapeutic effect of endostatin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Derivative of endostatin resistant to tumor proteins
  • Derivative of endostatin resistant to tumor proteins
  • Derivative of endostatin resistant to tumor proteins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1 A derivative of the anti-tumor protein endostatin, the derivative includes a fusion protein of endostatin linked to the constant region of antibody IgG, its anti-tumor activity and the half-life of the fusion protein in mice.

[0050] protein sample

[0051] Sample 1: pre-sequence-endostatin; the front of endostatin shown in SEQ ID NO.4 is connected with the pre-sequence shown in SEQ ID NO.2, and the signal peptide in the pre-sequence is to allow expressed endostatin can be secreted extracellularly.

[0052] Sample 2: fusion protein of pre-sequence-endostatin-antibody IgG partial constant region CH1 (shown in SEQ ID NO.8, the nucleic acid sequence encoding SEQ ID NO.8 is shown in SEQ ID NO.7).

[0053] Sample 3: pre-sequence-endostatin-antibody IgG partial constant region CH1CH2 fusion protein (shown in SEQ ID NO.10, the nucleic acid sequence encoding SEQ ID NO.10 is shown in SEQ ID NO.9).

[0054] Sample 4: pre-sequence-endostatin-antibody IgG constant regi...

Embodiment 2

[0061] Example 2 Evaluation of the newly introduced Arg in front of the N-terminus of endostatin derivatives

[0062] Select the pre-sequence-endostatin-antibody IgG constant region fusion protein (SEQ ID NO.11 and SEQ ID NO.12) of Example 4 of Example 1 as the experimental material, and illustrate it with the amino acid sequence (SEQ ID NO.12) , 1-23 amino acids are derived from albumin, 1-18 is the signal peptide of albumin, 19-23 are the 5 amino acids at the N-terminal of mature albumin, of which there are two Arg, 24-206 are endostatin, 207-536 is the constant region of antibody IgG, which consists of CH1, CH2 and CH3. Various experimental proteins:

[0063] Sample 1: pre-sequence-endostatin-antibody IgG constant region fusion protein, shown by SEQ ID NO.12, wherein 19-23 are Arg-Gly-Val-Phe-Arg.

[0064] Sample 2: pre-sequence-endostatin-antibody IgG constant region fusion protein point mutant 1, in which 19-23 is Ala-Gly-Val-Phe-Arg, the agg point mutation of the 19th ...

Embodiment 3

[0071] Example 3 Checking the Effect of Glycosylation Sites on the Activity of Endostatin Fusion Protein

[0072] The pre-sequence-endostatin-antibody IgG constant region CH1CH2CH3 fusion protein (SEQ ID NO.11 and SEQ ID NO.12) of Example 1 was used as the experimental material to construct derivatives, that is, the N-terminal front of endostatin or A glycosylated amino acid short peptide Gly-Ala-Ser-Asn-Ser-Thr-Gly-Ala-Ser is added behind the C-terminus, where Asn-Ser-Thr is the position of glycosylation, and the sugar chain is connected to Asn. Select embodiment 1 to express the plasmid (pHEK293 of the front sequence-endostatin-antibody IgG constant region CH1CH2CH3 fusion protein (shown in SEQ ID NO.12, encoding the nucleic acid sequence SEQ ID NO.11 of SEQ ID NO.12) Ultra Expression Vector II) for various gene manipulations, and the gene fragments of these mutants can also be directly synthesized, and then inserted into the plasmid (pHEK293 Ultra Expression Vector II) to e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a derivative of endostatin resistant to tumor proteins. The amino acid sequence of the endostatin is shown as SEQ.ID.NO4; point mutation of one of Arg128 and Arg129 of the amino acid sequence of the derivative occurs. The derivative of endostatin resistant to tumor proteins is stable in the body, long in half-life period and high in antitumor biological activity.

Description

technical field [0001] The invention relates to a derivative of anti-tumor protein endostatin and its application, belonging to the field of biomedical anti-tumor drugs. Background technique [0002] Tumor growth depends on the formation of blood vessels, and the formation of blood vessels is regulated by angiogenesis factors and inhibitors. Inhibiting the growth of tumor blood vessels is an effective way to treat tumors. Endostatin (Endostatin) has the function of inhibiting angiogenesis, so it has been paid attention to in the anti-angiogenesis treatment of tumors. Endostatin is a C-terminal 184 amino acid fragment produced by the hydrolysis of collagen XVIII. It can effectively inhibit a variety of different types of tumors. Its biological effects are broad-spectrum and have no drug resistance. It is the best discovered so far. Angiogenesis inhibitors (Exp Cell Res, 312, 594-607, 2006). [0003] However, in monkey experiments and human clinical trials, it was found that...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/78C07K19/00A61K38/39A61K47/68A61P35/00
Inventor 孙嘉琳
Owner 孙嘉琳
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com